Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 12/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194763 | 0.86 | JAK2 (0.50) | MAPK10JAK2FLT3MGLLPIK3CA | |
| SCHEMBL10194698 | 0.86 | MAPK10 (0.49) | MAPK10JAK2FLT3PIK3CA | |
| SCHEMBL10194703 | 0.83 | ALDH1A1 (0.46) | FLT3 | |
| SCHEMBL10196821 | 0.82 | JAK2 (0.46) | MAPK10JAK2FLT3MGLLPIK3CA | |
| SCHEMBL10194768 | 0.81 | FLT3 (0.55) | MAPK10JAK2FLT3MAPK8PIK3CA | |
| SCHEMBL10194932 | 0.81 | MAPK10 (0.45) | MAPK10JAK2FLT3 | |
| SCHEMBL10194781 | 0.81 | JAK2 (0.49) | MAPK10JAK2FLT3PIK3CA | |
| SCHEMBL10194764 | 0.81 | JAK2 (0.49) | MAPK10JAK2FLT3MAPK8PIK3CA | |
| SCHEMBL10194757 | 0.81 | JAK2 (0.49) | MAPK10JAK2FLT3MAPK8PIK3CA | |
| SCHEMBL9951916 | 0.81 | JAK2 (0.49) | MAPK10JAK2FLT3MAPK8PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | MAPK10 1774/4885JAK2 66/4885FLT3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.